Plamumab 40 mg PFS
$246.83
$86.70
Plamumab 40 mg is a therapeutic injection designed to effectively manage a range of inflammatory conditions, such as ankylosing spondylitis, rheumatoid arthritis, psoriasis, ulcerative colitis, and Crohn's disease. This advanced treatment is classified as a disease-modifying anti-rheumatic drug (DMARD) and functions as a monoclonal antibody, specifically targeting and neutralizing tumor necrosis factor-alpha (TNFα), a key player in the inflammatory process. By inhibiting TNFα, Plamumab 40 mg helps alleviate symptoms like swelling, pain, and redness, ultimately enhancing the quality of life and physical functionality for patients. It is essential to be aware of potential side effects, including increased risk of infections, and to discuss any existing medical conditions or medications with a healthcare provider prior to starting treatment. Regular monitoring and communication with your doctor are crucial to ensure safe and effective use of this medication. Plamumab 40 mg is a promising option for individuals seeking relief from chronic inflammatory conditions, offering both symptom management and improved overall health. Always follow your healthcare professional's guidance regarding dosage and administration for optimal results.
मात्रा
Active Pharmaceutical Ingredient
Uses
• Plamumab 40 mg pfs is primarily indicated for the treatment of rheumatoid arthritis, a chronic inflammatory disorder affecting the joints. This medication helps to reduce inflammation and alleviate pain, improving the overall quality of life for patients. By modulating the immune response, Plamumab 40 mg pfs aids in controlling the symptoms associated with this condition. It is commonly prescribed for adults who have not responded adequately to other treatments.
• Another key use of Plamumab 40 mg pfs is in managing ankylosing spondylitis, a type of arthritis that primarily affects the spine. This medication can help reduce stiffness and pain, allowing individuals to maintain better mobility. Patients typically notice improvements in their physical function and a decrease in discomfort with ongoing treatment. Plamumab 40 mg pfs serves as an essential option for those seeking relief from this chronic condition.
• Plamumab 40 mg pfs is also effective in treating inflammatory bowel diseases such as Crohn's disease and ulcerative colitis. These conditions cause significant gastrointestinal symptoms, and this medication helps to manage inflammation in the digestive tract. By doing so, Plamumab 40 mg pfs can lead to fewer flare-ups and an improved quality of life for affected individuals. It is often utilized in patients who require more aggressive treatment strategies.
• In addition to the above conditions, Plamumab 40 mg pfs is indicated for skin disorders like plaque psoriasis and hidradenitis suppurativa. This medication works by targeting specific pathways in the immune system, thereby reducing the severity of skin lesions and improving overall skin health. Patients using Plamumab 40 mg pfs may experience a significant reduction in symptoms, enabling them to engage more fully in daily activities. It is particularly beneficial for those who have not achieved satisfactory results with other therapies.
Benefits
Rheumatoid arthritis: Rheumatoid arthritis (RA) is a chronic autoimmune disease that primarily affects the joints. It causes inflammation, pain, stiffness, and swelling in the joints and can also affect other parts of the body, such as the skin, eyes, lungs, heart, and blood vessels. Plamumab 40 mg PFS helps reduce inflammation and manage the symptoms of rheumatoid arthritis.
Ankylosing spondylitis: Ankylosing spondylitis (AS) is a chronic inflammatory disease that primarily affects the spine, causing pain, stiffness, and reduced mobility. It is a form of arthritis that mainly affects the joints between the vertebrae in the spine and the sacroiliac joints where the spine connects to the pelvis. Adalimumab Injection 40 mg works by targeting and inhibiting tumor necrosis factor (TNF), a protein involved in inflammation. By reducing the inflammation associated with ankylosing spondylitis, Plamumab 40 mg PFS can help relieve pain, stiffness, and other symptoms of the condition.
Crohn's disease: Crohn's disease is a chronic inflammatory bowel disease (IBD) that primarily affects the gastrointestinal tract. It can cause inflammation and damage to any part of the digestive system, from the mouth to the anus. Symptoms of Crohn's disease can vary but commonly include abdominal pain, diarrhea, weight loss, fatigue, and loss of appetite. Plamumab Injection works by targeting and inhibiting tumor necrosis factor (TNF), a protein involved in inflammation. By reducing inflammation in the gastrointestinal tract, Plamumab 40 mg PFS can help manage the symptoms of Crohn's disease, including abdominal pain, diarrhea, and inflammation.
Ulcerative colitis: Ulcerative colitis is a chronic inflammatory bowel disease that primarily affects the colon and rectum. Adalimumab Injection 40 mg can help reduce inflammation in the gastrointestinal tract and manage the symptoms of ulcerative colitis.
Hidradenitis suppurativa: Hidradenitis suppurativa (HS) is a chronic inflammatory skin condition that affects the hair follicles in areas of the body with a high concentration of sweat glands, such as the armpits, groin, and buttocks. Plamumab 40 mg works by targeting and inhibiting tumor necrosis factor (TNF), a protein involved in inflammation. By reducing inflammation, Plamumab 40 mg PFS can help alleviate symptoms and prevent the progression of hidradenitis suppurativa.
Juvenile idiopathic arthritis: Juvenile idiopathic arthritis (JIA) is a type of arthritis that occurs in children under the age of 16 and persists for at least six weeks. It is characterized by joint inflammation, pain, stiffness, and swelling. Anti-inflammatory Drug Plamumab works by inhibiting tumor necrosis factor (TNF), a protein involved in inflammation. By reducing inflammation in the joints, adalimumab helps manage the symptoms of juvenile idiopathic arthritis, including pain, stiffness, and swelling.
Plaque psoriasis: Psoriasis is a condition where the skin cells in the body grow too quickly and form scales and dry patches. They can grow anywhere, but most appear on the scalp, elbows, knees, and lower back. Adalimumab Injection 40 mg reduces the scaly, itchy patches that may develop on the different parts of the body. It may take several months to become fully effective. You should avoid drinking alcohol while having this treatment and drink plenty of water to stay hydrated.
Psoriatic arthritis: Psoriatic arthritis is a type of inflammatory arthritis that occurs in some individuals with psoriasis, a chronic skin condition. It causes joint pain, swelling, and stiffness and can affect any joint in the body. Plamumab 40 mg PFS works by inhibiting tumor necrosis factor (TNF), a protein involved in inflammation. By reducing inflammation in the joints, adalimumab can help manage the symptoms of psoriatic arthritis, including joint pain, stiffness, and swelling.
Uveitis: Uveitis refers to the inflammation of the uvea, which is the middle layer of the eye. It can affect various parts of the uvea, including the iris, ciliary body, and choroid. Anti-inflammatory Drug Plamumab is a tumor necrosis factor (TNF) inhibitor that helps reduce inflammation by targeting TNF, a protein involved in the immune response.
Side Effects
As with all medicines, Anti-inflammatory Drug Plamumab may cause side effects that do not require medical attention and that will disappear as your body adjusts to the medicine. If they persist or you're concerned about them, tell your doctor.
Most Common Side Effects
• Headache
• Rashes
• Sinusitis
• Nausea
• Fever
• Itching
• uneasiness
• Urinary tract infection
• Red scaly patches
• Tingling and Numbness
• Vision problems
• limb weakness
• Respiratory distress
• Chest pain hives
• sore throat
• Pale skin
• Dizziness
Common Side Effects
• Irregular heartbeats
• Heart failure (symptoms
• rapid breathing, pedal oedema, tachypnea)
• Muscle weakness
• Difficulty in movements like speaking, chewing, swallowing
• Vision changes
• Altered liver function, especially in those people who are exposed to Hepatitis B virus
How To Use
Plamumab 40 mg PFS is given subcutaneously (under the skin) from any health care professional. Dosage and frequency will be decided by your doctor as per your disease condition and several other factors.
Safety Advice
• Alcohol: It is generally not recommended to drink alcohol while taking Plamumab Injection. It may increase the risk of liver damage. it is best to avoid alcohol or limit your alcohol consumption while taking any medication.
• Kidney: Patients with kidney disease should closely monitor kidney function while taking Plamumab 40 mg PFS and report any unusual symptoms or changes in kidney function to their physician. The dose of Plamumab 40 mg should be used with caution in patients with kidney disease. It is important to adjust the dose in patients with kidney disease.
• Breastfeeding: Plamumab 40 mg is probably safe to use during breastfeeding. Limited human data suggests that the drug does not represent any significant risk to the baby.
• Liver: Plamumab 40 mg PFS should be used with caution in patients with liver disease. It is important that patients with liver disease closely monitor liver function while taking Anti-inflammatory Drug Plamumab and report any unusual symptoms or changes in liver function to their doctor. The dose of Plamumab Injection may need to be adjusted in patients with liver disease.
• Pregnancy: Adalimumab Injection 40 mg is generally considered safe to use during pregnancy. Animal studies have shown low or no adverse effects on the developing baby; however, there are limited human studies.
• Driving: Plamumab 40 mg PFS may cause dizziness, fatigue, and difficulty concentrating and coordinating, which may affect your ability to drive a vehicle safely. It is important to follow your doctor's instructions and take necessary precautions, such as avoiding driving a vehicle or operating heavy machinery if you suffer from the side effects of this Plamumab Injection.